Search results
Showing 331 to 345 of 726 results for innovative
GaitSmart rehabilitation exercise programme for gait and mobility issues (HTG716)
Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.
Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)
Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.
Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults.
NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .
PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis (MIB313)
NICE has developed a medtech innovation briefing (MIB) on PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis .
HemaClear for bloodless surgical field during limb surgery (MIB187)
NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .
NICE has developed a medtech innovation briefing (MIB) on Accuro for guiding epidural or spinal anaesthesia .
NPi-200 for pupillary light reflex in critical care patients (MIB235)
NICE has developed a medtech innovation briefing (MIB) on NPi-200 for pupillary light reflex in critical care patients .
NICE has developed a medtech innovation briefing (MIB) on Acumen IQ sensor for predicting hypotension risk .
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)
NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .
CerebAir for continuous EEG monitoring in intensive care (MIB279)
NICE has developed a medtech innovation briefing (MIB) on CerebAir for continuous EEG monitoring in intensive care .
Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Medical technologies evaluation programme process guide (PMG34)
This process guide describes how NICE selects medical technologies for development of NICE guidance. It also describes how the medical technologies advisory committee develops guidance on selected technologies routed to it